AlphaMadera
Amgen Inc. (AMGN)
$462.31
+5.28 (+1.15%)Delayed quote.
Price history
Daily close- Start
- $296.30
- Latest close
- $466.01
- Period change
- +57.28%
- Period low
- $296.30
- Period high
- $466.01
Key metrics
- Market cap
- $251.94B
- Volume
- 3.29M
- Average volume
- 2.68M
- 52-week range
- $292.12 – $475.65
- Beta
- 0.41
- Last dividend
- $9.94
- EPS (TTM)
- $16.22
- P/E ratio
- 28.50
- Revenue (TTM)
- $38.12B
- Net income (TTM)
- $8.74B
- Total assets
- $95.64B
- Total debt
- $57.30B
- Cash and equivalents
- $13.99B
Key financials (trailing twelve months).
Company profile
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NASDAQ
- CEO
- Robert A. Bradway
- Employees
- 31,500
- Headquarters
- Thousand Oaks, CA, US
- IPO date
- 1983-06-17
- Website
- https://www.amgen.com
Financial statements
Annual, last 3 fiscal years. Most recent period first. Reported in USD.
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Revenue | $36.74B | $33.42B | $28.19B |
| Gross profit | $26.01B | $20.57B | $19.77B |
| Operating income | $10.68B | $7.26B | $7.90B |
| EBITDA | $16.90B | $13.36B | $14.80B |
| Net income | $7.71B | $4.09B | $6.72B |
| Diluted EPS | $14.23 | $7.56 | $12.49 |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $9.13B | $11.97B | $10.94B |
| Total assets | $90.59B | $91.84B | $97.15B |
| Total liabilities | $81.93B | $85.96B | $90.92B |
| Total debt | $54.60B | $60.10B | $64.61B |
| Shareholders’ equity | $8.66B | $5.88B | $6.23B |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | $9.96B | $11.49B | $8.47B |
| Capital expenditure | -$1.86B | -$1.10B | -$1.11B |
| Free cash flow | $8.10B | $10.39B | $7.36B |
Quarterly, last 6 quarters. Most recent period first. Reported in USD.
| Metric | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 | Q1 2025Mar 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue | $10.05B | $8.62B | $9.90B | $9.56B | $9.17B | $8.15B |
| Gross profit | $7.24B | $5.87B | $8.11B | $6.47B | $6.16B | $5.18B |
| Operating income | $3.51B | $2.67B | $3.94B | $2.53B | $2.64B | $1.18B |
| EBITDA | $4.55B | $3.86B | $3.30B | $5.91B | $3.62B | $4.08B |
| Net income | $2.38B | $1.82B | $1.33B | $3.22B | $1.43B | $1.73B |
| Diluted EPS | $4.37 | $3.34 | $2.45 | $5.93 | $2.65 | $3.20 |
| Metric | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 | Q1 2025Mar 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $13.99B | $12.04B | $9.13B | $9.45B | $8.03B | $8.81B |
| Total assets | $95.64B | $92.50B | $90.59B | $90.14B | $87.90B | $89.37B |
| Total liabilities | $83.95B | $83.31B | $81.93B | $80.52B | $80.47B | $83.16B |
| Total debt | $57.30B | $57.32B | $54.60B | $54.59B | $56.20B | $57.38B |
| Shareholders’ equity | $11.69B | $9.19B | $8.66B | $9.62B | $7.43B | $6.21B |
| Metric | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 | Q1 2025Mar 31, 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $4.00B | $2.19B | $1.60B | $4.68B | $2.28B | $1.39B |
| Capital expenditure | -$513.00M | -$712.00M | -$642.00M | -$436.00M | -$369.00M | -$411.00M |
| Free cash flow | $3.49B | $1.48B | $961.00M | $4.25B | $1.91B | $980.00M |